Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of KCONVAC in Healthy Children and Adolescents
NCT05003479Phase 1Unknown
- Sponsor
- Shenzhen Kangtai Biological Products
- Start
- Aug 2021
- Primary completion
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing KCONVAC with Placebo (2 arms). Primary endpoint: Incidence of adverse reactions/events. Status: unknown.
02
Drugs
KCONVAC
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05003479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05003479.